newsfilter
← Earnings
Earnings Releases·

Clene Inc. — Third Quarter 2026 Earnings Summary

  • Revenue reached $56,000 for the quarter ended September 30, 2026, up from $15,000 in the prior year, driven by $43,000 in product revenue; net income turned positive at $3.9 million ($0.30 basic EPS), reversing an $8.8 million loss in the same period last year.
  • Cash and cash equivalents increased to $9.9 million as of September 30, 2026, from $5.2 million at year-end 2025, with a $4.0 million registered direct offering in September expected to fund operations through mid-first quarter 2027.
  • The company submitted an NDA to the FDA in October 2026 for CNM-Au8 in ALS, expressing confidence in the review process, while planning to randomize the first participants for the Phase 3 RESTORE-ALS trial in the second quarter of 2027.
  • Total other income, net, was $10.3 million for the quarter, primarily driven by a $7.493 million change in the fair value of warrant liabilities and a $3.368 million change in derivative liabilities.
Company
CLENE INC
Sector
Healthcare
Industry
Biotechnology